The impact of postsynaptic density 95 blocking peptide (Tat-NR2B9c) and an iNOS inhibitor (1400W) on proteomic profile of the hippocampus in C57BL/6J mouse model of kainate-induced epileptogenesis



Tse, Karen, Hammond, Dean ORCID: 0000-0002-6326-8739, Simpson, Deborah ORCID: 0000-0002-3962-4895, Beynon, Robert J ORCID: 0000-0003-0857-495X, Beamer, Edward, Tymianski, Michael, Salter, Michael W, Sills, Graeme J ORCID: 0000-0002-3389-8713 and Thippeswamy, Thimmasettappa
(2019) The impact of postsynaptic density 95 blocking peptide (Tat-NR2B9c) and an iNOS inhibitor (1400W) on proteomic profile of the hippocampus in C57BL/6J mouse model of kainate-induced epileptogenesis. JOURNAL OF NEUROSCIENCE RESEARCH, 97 (11). pp. 1378-1392.

[img] Text
Submitted copy- R2.pdf - Author Accepted Manuscript

Download (12MB) | Preview

Abstract

Antiepileptogenic agents that prevent the development of epilepsy following a brain insult remain the holy grail of epilepsy therapeutics. We have employed a label-free proteomic approach that allows quantification of large numbers of brain-expressed proteins in a single analysis in the mouse (male C57BL/6J) kainate (KA) model of epileptogenesis. In addition, we have incorporated two putative antiepileptogenic drugs, postsynaptic density protein-95 blocking peptide (PSD95BP or Tat-NR2B9c) and a highly selective inducible nitric oxide synthase inhibitor, 1400W, to give an insight into how such agents might ameliorate epileptogenesis. The test drugs were administered after the induction of status epilepticus (SE) and the animals were euthanized at 7 days, their hippocampi removed, and subjected to LC-MS/MS analysis. A total of 2,579 proteins were identified; their normalized abundance was compared between treatment groups using ANOVA, with correction for multiple testing by false discovery rate. Significantly altered proteins were subjected to gene ontology and KEGG pathway enrichment analyses. KA-induced SE was most robustly associated with an alteration in the abundance of proteins involved in neuroinflammation, including heat shock protein beta-1 (HSP27), glial fibrillary acidic protein, and CD44 antigen. Treatment with PSD95BP or 1400W moderated the abundance of several of these proteins plus that of secretogranin and Src substrate cortactin. Pathway analysis identified the glutamatergic synapse as a key target for both drugs. Our observations require validation in a larger-scale investigation, with candidate proteins explored in more detail. Nevertheless, this study has identified several mechanisms by which epilepsy might develop and several targets for novel drug development. OPEN PRACTICES: This article has been awarded Open Data. All materials and data are publicly accessible as supporting information. Learn more about the Open Practices badges from the Center for Open Science: https://osf.io/tvyxz/wiki.

Item Type: Article
Uncontrolled Keywords: disease modification, glutamatergic synapse, inducible nitric oxide synthase (iNOS), neuroinflammation, postsynaptic density
Depositing User: Symplectic Admin
Date Deposited: 12 Jun 2019 12:30
Last Modified: 19 Jan 2023 00:43
DOI: 10.1002/jnr.24441
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3042607